US Stock MarketDetailed Quotes

PHVS Pharvaris

Watchlist
  • 15.450
  • +0.130+0.85%
Close Mar 4 16:00 ET
  • 15.450
  • 0.0000.00%
Post 20:01 ET
837.90MMarket Cap-5.59P/E (TTM)

About Pharvaris Company

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Company Profile

SymbolPHVS
Company NamePharvaris
Listing DateFeb 5, 2021
Issue Price20.00
Founded2015
CEOMr. Berndt Modig
MarketNASDAQ
Employees82
Fiscal Year Ends12-31
AddressEmmy Noetherweg 2
CityLeiden
ProvinceZuid-Holland
CountryNetherlands (the)
Zip Code2333 BK
Phone31-71-203-64-10

Company Executives

  • Name
  • Position
  • Salary
  • Berndt Modig
  • Chief Executive Officer and Executive Director
  • 935.28K
  • Joan Schmidt
  • Chief Legal Officer
  • --
  • Dr. Anne Lesage, PhD
  • Chief Early Development Officer
  • --
  • Dr. Peng Lu, M.D.,PhD
  • Chief Medical Officer
  • --
  • Dr. Wim Souverijns, PhD
  • Chief Community Engagement and Commercial Officer
  • --
  • Dr. Stefan Abele, PhD
  • Chief Technical Operations Officer
  • --
  • Dr. Morgan Conn, PhD
  • Chief Business Officer
  • --
  • Annick Deschoolmeester
  • Chief Human Resources Officer
  • --
  • Anna Nijdam, M.Sc.
  • Head of Strategic Finance and Principal Accounting Officer
  • --
  • Hans Schikan, Pharm.D.
  • Independent Director
  • 61.00K
  • Dr. Elisabeth Bjork, M.D.,PhD
  • Independent Director
  • 45.00K
  • Dr. David P. Meeker,M.D.
  • Independent Director
  • 94.00K
  • Viviane Monges
  • Independent Director
  • 62.50K
  • Dr. Robert Glassman, M.D.
  • Independent Director
  • 50.50K

Trending Stocks

Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More